The company is still reeling from the impact of expenses related to litigation, additional DePuy ASR Hip recall costs and the recent acquisition of Synthes. The company spent $233 million on litigation and recall expenses.
Read the financial report for DePuy Orthopaedics.
Related Articles to DePuy:
DePuy Orthopaedics’ Foot and Hip System Receive FDA 510(k) Clearance
DePuy Orthopaedics Names Andrew Ekdahl President
DePuy’s New Ceramic-on-Metal Hip Implant Receives FDA Clearance
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.